Inspire Medical Systems (INSP) reported $912M in revenue for fiscal 2025, +13.6% year on year. That ranks #1831 by revenue among 2853 SEC filers and #168 in Healthcare. Net income was $145M, a net margin of 15.9%. Revenue has grown 56.3% a year on average since 2016 ($16.4M then). The fiscal 2025 balance sheet shows $907M in total assets, $105M in cash and $24.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $912M | +13.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $779M | +14.6% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $51.0M | +41.2% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $145M | +171.8% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $117M | −10.2% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $38.5M | −1.6% | FY20252025-12-31 |
| Total assetsAssets | $907M | +12.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $781M | +13.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $105M | −30.2% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $24.5M | 0.0% | FY20212021-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $205M | −$11.3M | Open → |
| Q2 20262026-06-30 | $201M | $314,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Inspire Medical Systems, Inc.
- Ticker
- INSP
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001609550
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 4, 2026Open filing →
- 10-KFeb 13, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Ionis PharmaceuticalsIONS | $944M | −$381M |
| Usana Health SciencesUSNA | $925M | $10.8M |
| Tilray BrandsTLRY | $915M | −$121M |
| Inspire Medical SystemsINSP | $912M | $145M |
| Ani PharmaceuticalsANIP | $883M | $78.0M |
| Biocryst PharmaceuticalsBCRX | $875M | $264M |
| Warby ParkerWRBY | $872M | $1.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Inspire Medical Systems — Key figures |url=https://companiesranked.com/en/company/inspire-medical-systems |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Inspire Medical Systems — Key figures. CompaniesRanked. https://companiesranked.com/en/company/inspire-medical-systemsBibTeX
@misc{companiesranked-en-company-inspire-medical-systems-2026,
author = {{CompaniesRanked}},
title = {{Inspire Medical Systems — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/inspire-medical-systems}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001609550-26-000016 · February 13, 2026
{{cite web |title=Inspire Medical Systems — Key figures — 10-K (0001609550-26-000016) |url=https://www.sec.gov/Archives/edgar/data/1609550/000160955026000016/insp-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-13}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.